Wednesday, March 31, 2021

FCA hires Clark Ogilvie as new general counsel following retirement of Charlie Rawls

FCA hires Clark Ogilvie as new general counsel following retirement of Charlie Rawls
Farm Credit Administration Banner

News Release

For Immediate Release

Contact: Mike Stokke or Emily Yaghmour, 703-883-4056

Email: info-line@fca.gov


FCA hires Clark Ogilvie as new general counsel following retirement of Charlie Rawls


McLEAN, Va., March 31, 2021 — The Farm Credit Administration has selected Clark Ogilvie to serve as its new general counsel. Its current general counsel, Charlie Rawls, retires today. Mr. Ogilvie's first day on the job is April 11, and Joy Strickland, currently FCA's acting deputy general counsel, will serve as acting general counsel until then.

Mr. Ogilvie currently serves as special counsel in the Legal Division at the Commodity Futures Trading Commission (CFTC) in Washington, D.C. He first joined the CFTC in 2014 where he served for almost three years as chief of staff to then-Chairman Tim Massad.

From 2005 until 2014, Mr. Ogilvie was on the staff of the U.S. House Committee on Agriculture, where he worked on the Dodd-Frank Act; the Food, Conservation, and Energy Act of 2008; and the Agricultural Act of 2014. He briefly returned to the House Agriculture Committee in 2018, providing legal counsel for the 2018 Farm Bill regarding federal commodity programs, crop insurance, farm credit, rural development, forestry, and energy.

Before joining the staff of the House Agriculture Committee, he was a legislative assistant to Congressman Bob Etheridge of North Carolina for five years. Mr. Ogilvie has a law degree from George Washington University and a B.A. from Rhodes College. He is an associate member of the Virginia State Bar.

Mr. Ogilvie succeeds Charlie Rawls, who has been the agency's general counsel for the past 18 years, which is believed to be the longest tenure of any general counsel in the agency's history. Mr. Rawls has been an employee of the federal government for 38 years and has served in each of the three branches of the U.S. government.

Mr. Rawls worked briefly in the judicial branch as a law clerk, then moved to the legislative branch where he began as staff director for the House Agriculture Subcommittee on Forests, Family Farms, and Energy. Later, as deputy general counsel on the full House Agriculture Committee, he worked extensively on the Agricultural Credit Act of 1987, the landmark legislation that helped the Farm Credit System recover from the credit crisis of the 1980s.

Mr. Rawls moved to the executive branch of government in 1993 when he took a job as chief of staff to the deputy secretary of USDA. He went on to become deputy general counsel, and in 1998, he was confirmed by the Senate as general counsel of USDA. He later returned to the legislative branch to serve as general counsel to the Senate Committee on Agriculture, Nutrition, and Forestry, where he worked on the Farm Bill of 2002. He came to FCA in 2003.

"Charlie's legal counsel and leadership over the past 18 years has been exemplary," says FCA Board Chairman Glen Smith. "We have benefitted greatly not only from his legal expertise but also from his experience on the Hill. We will miss him professionally and personally but look forward to working with Clark, whose experience makes him an ideal successor."

"I've had the privilege of working closely with Charlie for the past six years," says FCA Board Member Jeff Hall. "He has the unusual ability to work with people with very different perspectives to find solutions that work for everyone. The agency has benefitted tremendously from his service. I also have full confidence in Clark's ability to provide the leadership we need in the years to come."


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: Farm Credit Administration · 1501 Farm Credit Drive ·
McLean, VA · 22102-5090
GovDelivery logo

UPDATE - Investigation of Acute Non-viral Hepatitis Illnesses – “Real Water” Brand Alkaline Water

US Food and Drug Administration

Outbreak Investigations & Safety Advisories

Center for Food Safety and Applied Nutrition 

The following is an update from FDA of concern to our subscribers.

Investigation of Acute Non-viral Hepatitis Illnesses – "Real Water" Brand Alkaline Water (March 2021)

March 31, 2021

The FDA, along with the CDC and the Southern Nevada Health District, is investigating a number of reports of acute non-viral hepatitis in the state of Nevada associated with "Real Water" brand alkaline water.

The FDA has become aware that "Real Water" brand alkaline water is still being offered for sale through online retailers. The agency is working to locate any remaining products to ensure they are no longer available to consumers. The FDA will continue to monitor this situation closely and follow up with retailers as we become aware of recalled products being offered for sale.

In addition, the FDA is conducting an audit to gauge the effectiveness of the voluntary recall initiated by Real Water, Inc. As of March 31, 2021, the audit has found that, prior to contact by FDA, a number of distributors had not received notification directly from the firm about the recall. Additionally, as of March 31 2021, Real Water Inc. is still promoting the product via social media despite issuing a recall announcement.

Therefore, the FDA is reiterating that it is crucial that consumers, restaurants, distributors, and retailers not drink, cook with, sell, or serve "Real Water" alkaline water.

Given a lack of cooperation by the firm, FDA investigators have been unable to complete investigations at the "Real Water" Inc. facilities in Henderson, NV and Mesa, AZ and have not been provided with requested records. As a result, on March 23 and on March 25, FDA issued a Demand for Records under section 414 of the Federal Food, Drug, and Cosmetic Act.

Consumption of "Real Water" brand alkaline water is the only common link identified among all of these cases to date. This brand of alkaline water is owned by Real Water Inc., headquartered in Mesa, Arizona.

Although the investigation is ongoing, current epidemiologic information indicates that this alkaline water product may be the cause of the illnesses.

As this outbreak investigation continues, the FDA will provide additional updates to this advisory as more information becomes available.

Recommendation

Consumers, restaurants, distributors, and retailers should not drink, cook with, sell, or serve "Real Water" alkaline water, until more information is known about the cause of the illnesses. Further, FDA advises that this water not be served to pets. These products include but are not limited to: 5-gallon and 3-gallon containers (sold through home delivery/subscription), bottles of various sizes (sold on-line and in stores), and the "Real Water" concentrate (sold on-line).

The public is urged to report any product being offered for sale to the FDA Consumer Complaint Coordinator in their region.

According to the firm's press release, the recalled alkaline water products are available nationwide, however the 5-gallon containers were distributed to the following areas: greater Las Vegas, NV area, central California coastal region (North of Los Angeles, CA, and South from Santa Barbara, CA), and Phoenix, AZ.

The firm's press release also includes 1.5 liter, 1 liter, 500 ml and 1 gallon ready-to-drink alkaline water bottles and the 4 oz. concentrate.

Symptoms of all types of hepatitis, including non-viral hepatitis, are similar and can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay or gray-colored bowel movements, joint pain, yellow eyes, and jaundice. Those experiencing these symptoms should contact their doctor.

Read the full update


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

FDA MedWatch - Lamictal (lamotrigine): Drug Safety Communication

Studies Show Increased Risk of Heart Rhythm Problems in Patients with Heart Disease

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

A Central, Southern and Northern Thai Food Tour Of Sydney!

Hello Everyone!

Here's your daily Not Quite Nigella email with my latest post. I hope that you enjoy it and feel free to pass it onto friends too if you think that they will like it :)

A Central, Southern and Northern Thai Food Tour Of Sydney!

Image: A Central, Southern and Northern Thai Food Tour Of Sydney!

If you're missing travelling overseas, take your own little holiday in Thaitown Sydney and explore food from the Southern, Northern and Central Thailand regions. At Caysorn there's spicy, bold Southern Thai food while Show Neua showcases Northern Thai cuisine with influences from Laos, Burma and China. Then there's Central Thai food at @Bangkok, which is a milder mixing of them all! Continue »

Best wishes,

Lorraine

xxx

www.notquitenigella.com

 


If you no longer want me to email you, click this link to remove your email address.

Save the Date: The FDA’s Virtual Town Hall for Test Developers on Coronavirus (COVID-19) Test Development and Validation

April 2021 dates announced

If your email program has trouble displaying this email, view as a webpage.

CDRH Webinars Banner

April 2021 Dates Announced for the Virtual Town Hall Series for Test Developers on Coronavirus (COVID-19)

The U.S. Food and Drug Administration (FDA) will continue hosting virtual Town Halls for test developers for SARS-CoV-2 in April on the following dates:

  • April 7, 2021 from 12:15 pm – 1:15 pm Eastern Time
  • April 14, 2021 from 12:15 pm – 1:15 pm Eastern Time
  • April 21, 2021 from 12:15 pm – 1:15 pm Eastern Time
  • April 28, 2021 from 12:15 pm – 1:15 pm Eastern Time

During the virtual Town Hall, the FDA will share information and answer your questions about the development and validation of tests for SARS-CoV-2. Registration is not required.

If you are unable to attend the live virtual Town Hall, the recording and transcript will be available for viewing the Tuesday after the live event.

View the Webinar Details

Questions?

For general questions, including about this Town Hall, contact Division of Industry and Consumer Education.

For specific questions about COVID-19 diagnostic development, contact CDRH-EUA-Templates@fda.hhs.gov.


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

Accelerating Medical Device Innovation with Regulatory Science Tools

19 new tools added to the Catalog of Regulatory Science tools in March.

If your email program has trouble displaying this email, view as a webpage.

US Food and Drug Administration

Regulatory Science Tools to Accelerate Medical Device Innovation: FDA Voices

As the rate of technological advances moves faster than the science for evaluating the benefits and risks of new products, the FDA's Center for Devices and Radiological Health (CDRH) is helping to ensure that device developers have the right test methods to evaluate new innovations.

The Catalog of Regulatory Science Tools collates a variety of regulatory science tools that CDRH's Office of Science and Engineering Labs (OSEL) has developed, with new tools added as they become available. These methods expand the scope of innovative science-based approaches to improve the development and assessment of emerging medical technologies. The catalog includes more than 100 tools, including laboratory methods, tissue-mimicking phantoms, and computational modelling and simulations

In addition to helping device developers identify appropriate tools for their needs, the catalog entries include detailed instructions for use and, where appropriate, reference to the original peer reviewed source for further detail.

Read More

The catalog includes more than 100 tools, including laboratory methods, tissue-mimicking phantoms, and computational modelling and simulations. In March 2021, the FDA added 19 tools to the catalog:

  • Correction for Hydrophone Spatial Averaging Artifacts for Circular Sources
  • Experimental and computational methods for the acoustic and thermal characterization of therapeutic ultrasound fields
  • Acoustic power calibration of high-intensity focused ultrasound transducers using a radiation force technique
  • Framework for quantitatively estimating ultrasound beam intensities using infrared thermography
  • Full-Field Microscale Strain Measurements of a Nitinol Medical Device Using Digital Image Correlation
  • An in vitro blood flow loop system for evaluating the thrombogenicity of medical devices and biomaterials
  • A Reusable, Compliant, Small Volume Blood Reservoir For In Vitro Hemolysis Testing
  • Limitations of using synthetic blood clots for measuring in vitro clot capture efficiency of inferior vena cava filters
  • Plasma hemoglobin measurement techniques for the in vitro evaluation of blood damage caused by medical devices
  • Quantification by mass of residual debris in reusable medical devices
  • Method of Manufactured Solutions Code Verification of Elastostatic Solid Mechanics Problems in a Commercial Finite Element Solver
  • Use of the FDA Nozzle Model to Illustrate Validation Techniques in Computational Fluid Dynamics (CFD) Simulations
  • Verification benchmarks to assess the implementation of computational fluid dynamics based hemolysis prediction models
  • Fluid-Structure Interaction (FSI) Models of Bioprosthetic Heart Valve Dynamics (BHV) in an Experimental Pulse Duplicator
  • Orthopaedic SMART Devices Roadmap
  • Spinal Growing Rod Mechanical Performance Testing
  • Integrated Fixation Cage Fatigue Testing
  • Considerations for the selection of specimen size for cyclic potentiodynamic polarization corrosion susceptibility testing
  • Considerations for the pre-conditioning of specimens for cyclic potentiodynamic polarization corrosion susceptibility testing

View the Catalog

Questions?

If you have questions about this catalog of regulatory science tools, email OSEL_CDRH@fda.hhs.gov.


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo